Every round on record, with the sources behind each and the investors on them.
TangGene specializes in developing innovative therapies for autoimmune diseases using a proprietary nanoparticle platform to stimulate immune responses.
tanggene.comLinkedInNew BrunswickBiotech
2 sources · checked 4 times, last 3h ago
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The source describes an NJIEF investment approval rather than naming a conventional financing round; no round stage or valuation is stated.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| NJIEF investment | $1.5M | ~ 2026-10-16 | not stated | No recent discussion |
2 sources · checked 4 times, last 3h ago [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 2 sources
The source describes an NJIEF investment approval rather than naming a conventional financing round; no round stage or valuation is stated. | ||||
TangGene develops injectable nanoparticle therapies that reprogram the immune system to restore tolerance for people with multiple sclerosis and other autoimmune diseases.
Checked against 8 sources 3d ago
Also named as backers in company research: New Jersey Economic Development Authority